Clinical Trial Update: Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating addition of nivolumab to anti-CD-19 CAR-T cells in patients with B cell lymphoma undergoing lymphodepletion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Anti-CD-19 CAR-T cells (CD19-targeted chimeric antigen receptor T cells)
• nivolumab (nivolumab)

Snippet

Sponsor: Tel-Aviv Sourasky Medical Center | Conditions: B Cell Lymphoma | Phase 2 | Status: UNKNOWN